India Slashes Cancer Drug Prices by up to 70% as New Caps Take Effect
India’s drug regulator has capped trade margins on 137 anti-cancer medicines, cutting prices by up to 70% and saving patients an estimated ₹3,357 crore a year.
India’s drug regulator has capped trade margins on 137 anti-cancer medicines, cutting prices by up to 70% and saving patients an estimated ₹3,357 crore a year.
Pfizer has lifted its full-year profit and sales forecasts after quarterly revenue beat expectations, driven by strong demand for its blood thinner Eliquis and its cancer medicines.
AstraZeneca has unveiled a restructuring programme expected to deliver about $1.5 billion in benefits to fund investment in its drug pipeline, after third-quarter results beat analyst expectations.